Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxymorphone Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
31
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 3, 2026, 12:09 PM EDT
Suspended Phase 3 Interventional

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

NCT04681027
View directory record Official record
Conditions
Chronic Pain, Postsurgical Pain
Interventions
Oxymorphone hydrochloride (HCl)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Orange, California • New Orleans, Louisiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

NCT03389750
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 3, 2026, 12:09 PM EDT
Completed No phase listed Observational

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

NCT04033094
View directory record Official record
Conditions
Baseline Epidemiologic Assessment
Interventions
MorphaBond ER, Comparator Drug
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Not listed
Enrollment
17,566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

NCT00225797
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
33
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

NCT00930943
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
MedVadis Research Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

NCT01210638
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 3, 2026, 12:09 PM EDT
Completed No phase listed Observational

Predicting Oxycodone Dose From Oral Fluid Drug Levels

NCT01928303
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 72 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

NCT00904280
View directory record Official record
Conditions
Cancers, Pain, Lower Back Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Phase 3 Interventional Results available

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

NCT02929589
View directory record Official record
Conditions
Pain, Hernia
Interventions
Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication
Drug
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
View directory record Official record
Conditions
Acute Pain
Interventions
Oxymorphone immediate release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 3, 2026, 12:09 PM EDT
Not listed Not applicable Interventional

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

NCT00945919
View directory record Official record
Conditions
Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Sep 3, 2026, 12:09 PM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Phase 4 Interventional Results available

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

NCT02741076
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions
Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Drug
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
61
States / cities
Foley, Alabama • Mobile, Alabama • Montgomery, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.

NCT00801398
View directory record Official record
Conditions
Postoperative Pain
Interventions
Oxymorphone IR
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Phase 4 Interventional Results available

Lumbar Stenosis Outcomes Research II

NCT00652093
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
opana then darvocet then placebo, opana then placebo then darvocet, placebo then opana then darvocet, Placebo then darvocet then opana, Darvocet then opana then placebo, Darvocet then placebo then opana
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Early Phase 1 Interventional

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

NCT03579446
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Hydrocodone, Hydromorphone, Levorphanol, Morphine, Oxycodone, Oxymorphone, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 3, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT01210352
View directory record Official record
Conditions
Post Operative Pain
Interventions
oxymorphone HCl
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
8
States / cities
Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 3, 2026, 12:09 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT02687451
View directory record Official record
Conditions
Post-Operative Pain, Acute Pain
Interventions
Oxymorphone HCl, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 2 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 3, 2026, 12:09 PM EDT